Experimental immune therapy tested for leukemia patients whose cancer returned after transplant
NCT ID NCT03912064
Summary
This early-stage trial is testing whether a combination of two immune-based treatments is safe for patients whose blood cancer has returned after a stem cell transplant. The study involves 25 adults with conditions like acute myeloid leukemia or myelodysplastic syndromes. Researchers want to find the highest safe dose of the drug ipilimumab when given with specially prepared immune cells from the original donor.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes NO responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for MYELOFIBROSIS are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
Brigham and Women's Hospital
Boston, Massachusetts, 02115, United States
-
Dana Farber Cancer Institute
Boston, Massachusetts, 02115, United States
Conditions
Explore the condition pages connected to this study.